Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

Mayo Clinic Proceedings

Volumn 82, Issue 10, 2007, Pages 1179-1184

  Lacy, Martha Q ^a   Gertz, Morie A ^a   Dispenzieri, Angela ^a   Hayman, Suzanne R ^a   Geyer, Susan ^a   Kabat, Brian ^a   Zeldenrust, Steven R ^a   Kumar, Shaji ^a   Greipp, Philip R ^a   Fonseca, Rafael ^b   Lust, John A ^a   Russell, Stephen J ^a   Kyle, Robert A ^a   Witzig, Thomas E ^a   Bergsagel, P Leif ^b   Stewart, A Keith ^b   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; M PROTEIN;

ADULT; ANXIETY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG DOSE TITRATION; FATIGUE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; RASH; SIDE EFFECT; STEM CELL MOBILIZATION; THROMBOSIS;

EID: 34848824393     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.10.1179     Document Type: Article

References (26)

1. Attal M, Harousseau JL, Stoppa AM, et al, Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335 (2):91-97.
2. Child JA, Morgan GJ, Davies FE, et al, Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875-1883.
3. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol. 1990;33(2);86-89.
4. Kyle RA, Rajkumar SV. Multiple myeloma [published correction appears in N Engl J Med. 2005;352(11)1163]. N Engl J Med 2004;351(18):1860- 1873.
5. Sirohi B, Powles R. Multiple myeloma. Lancet. 2004;363(9412):875- 887.
6. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20(21):4319-4323.
7. Wang M, Weber DM, Delasalle K, Alexanian R. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol. 2005;79(3):194-197.
8. Cavo M, Zamagni E, Tosi P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89(7):826-831.
9. Cavo M, Zamagni E, Tosi P, et al, Writing Committee of the Bologna 2002 Study. Superiority of thalidomide and dexamethasone over vincristine- doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005 Jul 1;106(1):35-39. Epub 2005 Mar 10.
10. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20;24(3):431-436. Epub 2005 Dec 19.
11. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9):2943-2950.
12. Richardson PG, Schlossman RL, Hideshima T, et al. A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thai) derivative, in patients with relapsed and refractory multiple myeloma (MM). Blood. 2001;98:775a. Abstract 3225.
13. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100(9):3063-3067.
14. Zangari M, Tricot G, Zeldis J, et al. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood. 2001 ;775a. Abstract 3226.
15. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15;108(10):3458-3464. Epub 2006 Jul 13.
16. Bennett CL, Angelotta C, Yarnold PR, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer, [letter]. JAMA. 2006;296(21):2558-2560.
17. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma, [letter]. NEngl JMed. 2006;354(19):2079-2080.
18. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood. 2005 Dec 15;106(13):4050-4053. Epub 2005 Aug 23.
19. Bladé J, Samson D, Reece D, et al. Myeloma Subcommittee of the EBMT (European Group for Blood and Marrow Transplant), Chronic Leukaemia Working Party, Myeloma Working Committee of the IBMTR (International Bone Marrow Transplant Registry), ABMTR (Autologous Blood and Marrow Transplant Registry). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5): 1115-1123.
20. Durie BGM, Harousseau J-L, Miguel JS, et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma [published corrections appear in Leukemia 2O06;20(12):2220, Leukemia 2007;21(5):1134]. Leukemia. 2006 Sep;20(9):1467-1473. Epub 2006 Jul 20.
21. Attal M, Harousseau JL, Facon T, et al, Intergroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495-2502.
22. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005;129(6):776-783.
23. Jagannath S, Richardson PG, Barlogie B, et al, SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006;91(7):929-934.
24. Chanan-Khan A, Miller KC Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma, [letter]. Leak Lymphoma. 2005;46(7):1103-1104.
25. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129(6):755-762.
26. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Greipp P. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood. 2006;108:239a. Abstract 799.